Evidence Based Hair

Latest Episodes:

Season 5 Episode 1 (LPP Disease Associations, LPP & Thyroid, Side Effects of HCQ, Genetic Basis of Male FFA, FFA Prevalence/Incidence) Jul 17, 2023

Show notes

DISEASE ASSOCIATIONS IN FRONTAL FIBROSING ALOPECIA

Conic et al. Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.

Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.

Lim SH Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235

THE RELATIONSHIP BETWEEN LPP AND HYPOTHYROIDISM

Joshi TP et al. Association of lichen planopilaris with hypothyroidism: a systematic review and meta-analysis. Int J Dermatol. 2023 Jul 10.

SIDE EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH SCARRING ALOPECIA

Ezemma O et al. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023 Apr 10. doi: 10.1111/ijd.16660. Online ahead of print

GENETICS OF MALE FRONTAL FIBROSING ALOPECIA

Rayinda T et al. Shared Genetic Risk Variants in Both Male and Female Frontal Fibrosing Alopecia. J Invest Dermatol. 2023 May 19;S0022-202X(23)02068-7.

INCIDENCE AND PREVALENCE OF FRONTAL FIBROSING ALOPECIA

Lavian J et al. Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. Dermatol Online J. 2021 Aug 15;27(8).

Trager MH et al. Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169

Carmona-Rodriquez M et al. Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases. Life (Basel). 2023 Jun 8;13(6):1344.

Season 4, Episode 8 (Isotretinoin for SD, Iron Therapy, Memantine for TTM, Antifungal Resistance Apr 09, 2023

Show notes

Season 4, Episode 8

Season 4, Episode7 (Tinea with baricitinib, ADHD and AA, Upadacitinib for AA, Baricitinib 52 week data, micro needling for MPHL) Apr 05, 2023

Show notes

Season 4, Episode 7 Data

Season 4, Episode 6 (Scalp Neuropathy in DMS, Scurvy, Cutaneous Pili Migrans, Quiz Case, Beethoven’s Hair) Mar 30, 2023

Show notes

Season4, Episode 6

Season 4, Episode 5 (Hair Loss after COIVD Vaccines, FD in DEB, New DSC ”CVG” Variants, DSC After HT, DLE to SLE Progression) Mar 22, 2023

Show notes

Season 4, Episode 5

Season 4, Episode 4 (COVID hair loss, TE from anti-CGRP migraine meds, tinea capitis, oral minoxidil for traction alopecia Mar 13, 2023

Show notes

Season 4 Episode 4

COVID RELATED TE

Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.

M Alharbi et al. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022 Oct;11(10):6056-6060.

Tahmaz A et al. [The Evaluation of Long Coronavirus Disease Symptoms at Ninth Month from a Hospital in Türkiye]. .Mikrobiyol Bul. 2022 Oct;56(4):657-666.

Saber M et al. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023 Mar 9

Lv S et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection Clin Cosmet Investig Dermatol. 2021; 14: 385–387. Published online 2021 Apr 16.

Willimann B, et al. Hair pain (trichodynia): frequency and relationship to hair loss and patient gender. Dermatology. 2002

HAIR LOSS FROM ANTI-CGRP THERAPIES

Ruiz M et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023 Feb;43(2):3331024221143538.

Sessa M and Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35: 215–227

Evers S and Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023 Jan;63(1):165-167.

ORAL MINOXIDIL FOR TRACTION ALOPECIA

Awad A et al. Low-dose oral minoxidil improves hair density in traction alopecia. J Am Acad Dermatol. 2023 Feb 24;S0190-9622(23)00278-5.

Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.

Kim and Craiglow. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.

TINEA CAPITIS WORK UP AND TREATMENT IN PEDIATRICS

Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

Season 4 Episode 3 (Spironolactone for FPHL, Oral Minoxidil for Nails, Histology of AA vs AGA, AAI, Work Productivity in AA) Mar 07, 2023

Show notes

Season 4, Episode 3

Season 4, Episode 2 (Scalp Bx for Black Women, Oral Minoxidil for Chemotherapy Hair Loss, Folliculotropic MF, Atrichia with Papular Lesions, MTX and Liver Fibrosis) Mar 01, 2023

Show notes

STUDIES REFERENCED

ROLE OF SCALP BIOPSIES IN BLACK WOMEN WITH HAIR LOSS

Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.

ORAL MINOXIDIL IN CHEMOTHERAPY RELATED HAIR LOSS

Kang J et al. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol 2022 Dec 13;S0190-9622(22)03261-3.

FOLLICULOTROPIC MYCOSIS FUNGOIDES

Paolino G et al. Widespread and eruptive comedonal lesions with alopecia. JAAD Case Rep . 2022 Nov 1;31:23-26.

Kreutzer and Effendy. Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides. Dermatol Ther (Heidelb). 2020 Oct;10(5):1175-1180

Gallo G et al Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports. 2021 May 18;11(1):10555.

ATRICHIA WITH PAPULES LESIONS

Boisen J et al. Atrichia With Papular Lesions Confirmed via Genetic Testing: A Case Report. Cureus 2022 Dec; 14(12): e32562.

Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol 2002; 118: 887–890

Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria. Acta Derm Venereol 2008; 88(4): 346–349.

Bergman R et al. The alopecias associated with vitamin D-dependent rickets type IIA and with hairless gene mutations: a comparative clinical, histologic, and immunohistochemical study. Arch Dermatol. 2005 Mar;141(3):343-51.

METHOTREXATE AND LIVER FIBROSIS

Atallah E et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol . 2023 Jan 23;S0168-8278(23)00020-X.

Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015;45(2):156–162

Cheema HI et al. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022 Oct;70(7):1452-1460.

Season 4, Episode 1 (HCQ and Retinopathy Risk, FD Microbiome, LDN for LPP, TNF Inhibitors for DSC) Feb 20, 2023

Show notes

STUDIES REFERENCED PATHOLOGY OF NON SCARRING AND SCARRING ALOPECIA Amanda Araujo Dos Reis Botega et al. Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study Skin Appendage Disord. 2023 Jan;9(1):34-41. doi: 10.1159/000526966. Epub 2022 Nov 25. HYDROXYCHLOROQUINE AND RETINOPATHY RISK Ronald B Melles RB et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 Jan 17. LOW DOSE NALTREXONE IN LICHEN PLANOPILARIS Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020 Hamel RK et al. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus Jan 2023. Toledo-Pastrana et al. Perifollicular Erythema as a Trichoscopy Sign of Progression in Frontal Fibrosing Alopecia. Int J Trichology. 2013 Jul-Sep; 5(3): 151–153. ACTINIC LICHEN PLANOPILARIS Lalagianni N et al. Actinic lichen planopilaris: a new variant of lichen planopilaris triggered by ultraviolet radiation. Clin Exp Dermatol. 2023 Feb 2;48(2):158-160. FOLLICULITIS DECALVANS MICROBIOME STUDIES Moreno-Arrones OM et al. Folliculitis decalvans has a heterogeneous microbiological signature and impaired immunological response. Dermatology. 2023 Jan 30. Moreno-Arrones et al. Folliculitis decalvans microbiologic signature is specific for disease clinical phenotype. J Am Acad Dermatol. 2021 Nov;85(5):1355-1357. TNF INHIBITORS IN DISSECTING CELLULITIS Alzahrani M et al. Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter STUDY. Clin Exp Dermatol. 2023 Jan 26;llad036.

Season Finale (PART 2 of 2): Top 20 Hair Research Studies of 2022 Dec 23, 2022

Show notes

The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in hair shedding, scarring alopecia, seborrheic dermatitis and hair straighteners (studies 12 to 20). Studies 1 to 11 are found in Part 1 (season 3 episode 9)

STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19

STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.

STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022

STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.

STUDIES IN SCARRING ALOPECIA

STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016

STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan

STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.

STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.

STUDIES IN VARIOUS TOPICS

STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.

STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.

STUDIES IN PART 1 of PODCAST

STUDIES IN AGA

STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645

STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.

STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;

STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.

STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.

STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.

STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36

STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.

STUDY 9: Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.

STUDIES IN ALOPECIA AREATA

STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.

STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected